332 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
Understanding the real-world effectiveness of combination therapies like Xultophy® is crucial for optimizing Type 2 Diabetes management. This study provides valuable data on how a fixed-ratio combination of insulin de…
Developing long-acting GLP-1 receptor agonists is paramount for improving patient adherence and convenience in the long-term management of Type 2 Diabetes. If LAPS-Exendin (HM11260C) demonstrates favorable safety and …
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
This study is crucial because it focuses on affordable and accessible interventions for a population disproportionately affected by metabolic and cardiovascular diseases. Identifying effective, well-tolerated, and cos…
This Phase 1 study is a crucial step in the development of a potentially improved oral semaglutide formulation. Understanding the pharmacokinetics of oral semaglutide D under various dosing conditions is essential for…
This large-scale data analysis is crucial for understanding the potential neuroprotective effects of different diabetes medications. If Semaglutide demonstrates a significantly lower risk of dementia/Alzheimer's disea…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
If successful, this trial could identify a novel dietary supplement, AMPK Charge+®, that effectively improves glycemic control in individuals with prediabetes or Type 2 Diabetes. The potential for AMPK Charge+® to enh…
Successfully managing the gastrointestinal side effects of incretin-based anti-obesity medications is crucial for improving patient compliance and achieving optimal weight loss outcomes. This study's findings could es…
This study is crucial for understanding how lifestyle interventions like endurance exercise can complement pharmacological treatments such as semaglutide in managing Type 2 Diabetes. The key implication is that a comb…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…
Developing new, potentially improved formulations of existing, effective drugs is crucial for enhancing patient convenience, adherence, and broader accessibility. If oral semaglutide D proves to be equally safe and ef…
The completion of this large Phase 3 trial is a significant milestone, as it represents a robust effort to explore a novel therapeutic avenue for Alzheimer's disease. If the results demonstrate a positive effect, it c…
Understanding the pharmacokinetic equivalence between daily and weekly dosing of semaglutide is crucial for optimizing drug development and patient care. If comparable steady-state exposure was achieved with daily adm…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
Demonstrating the clinical comparability of drug products from different manufacturing processes is crucial for ensuring consistent drug quality, safety, and patient outcomes globally. This study's findings, once rele…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
This review highlights a paradigm shift in how dysglycemia might be managed in acute care settings. If GLP-1 RAs prove safe and effective in this population, they could offer a novel therapeutic strategy to improve ou…
This pilot study is crucial because it addresses a significant unmet need for effective smoking cessation strategies in Type 2 diabetes patients, a group at high risk for cardiovascular complications. If semaglutide p…
The successful completion of this Phase 3 trial suggests semaglutide 2.4 mg could represent a significant advancement in the management of obesity and prediabetes. If the full results confirm substantial weight loss a…
If BGM0504 demonstrates comparable or superior efficacy to semaglutide with a favorable safety profile, it could represent a significant new therapeutic option for managing Type 2 Diabetes. This could provide a valuab…
If the results demonstrate a positive safety and efficacy profile, this study could pave the way for a novel adjunctive treatment strategy for a particularly challenging patient population. Adults with Type 1 Diabetes…
Establishing bioequivalence is crucial for pharmaceutical products, especially when manufacturing processes are altered, as it confirms that the drug's performance remains consistent. This finding means that patients …
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
The identification of genetic predictors for GLP-1 response holds significant implications for personalized medicine in managing prediabetes, type 2 diabetes, and obesity. This research could lead to tailored therapeu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…